

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of Michael John MONTEITH et al.

International Application No.: PCT/EPEP2004/007666

International Filing Date: July 8, 2004

For: Pharmaceutical Formulations Comprising Magnesium Stearate

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

Copies of the references are enclosed
 Copies of the references were submitted in parent application Serial No. _____.
(37 CFR 1.98(d))
 A copy of the International Search Report which issued on International Application No. PCT/EP2004/007669 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A. The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).


OR

The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

B. The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:
(1) a final action under § 1.113 or
(2) a notice of allowance under § 1.311,
whichever occurs first.

Express Mail Label No.: E113321309464S
Date of Mailing: 1/10/2006

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to "Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on the date shown above.


Patty Wilson

[] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

[] Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

C. [] The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

[] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. **[or]**

[] Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and

[] The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.

[X] Please charge any required fees to Deposit Account No.07-1392.

[] A duplicate copy of this paper is attached.

Respectfully Submitted,


J. Scott Young
Attorney of Record
Registration No. 45,582

Date: 10 Jan 2006

Customer No. 23347

GlaxoSmithKline

Corporate Intellectual Property

5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-8160

Facsimile: (919) 483-7988

FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT

INT'L FILING NO.	PCT/EP2004/007666
INT'L FILING DATE	7/8/2004
APPLICANT	Michael Monteith et al.
GROUP	
EXAMINER	
ATTORNEY DOCKET NO.	PB60385USw

U.S. PATENT DOCUMENTS

Examiner Initials	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	1. 5,202,309	4/13/1003	Schwartz et al.			
	2. 6,576,793	6/10/2003	Moran et al.			
	3. 6,747,043	6/8/2004	Moran et al.			

FOREIGN PATENT DOCUMENTS

	Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
4.	0069715	1/12/1983	EP			
5.	0237507	9/16/1987	EP			
6.	2064336	6/17/1981	GB			
7.	2129691	5/23/1984	GB			
8.	2169265	7/9/1986	GB			
9.	2178965	2/25/1987	GB			
10.	2242134	9/25/1991	GB			
11.	WO96/23485	8/8/1996	PCT			
12.	WO00/28979	5/25/2000	PCT			yes-abstract
13.	WO00/53158	9/14/2000	PCT			
14.	WO01/42193	6/14/2001	PCT			
15.	WO01/78694	10/25/2001	PCT			
16.	WO01/78695	10/25/2001	PCT			
17.	WO02/070490	9/12/2002	PCT			
18.	WO02/076933	10/3/2002	PCT			
19.	WO02/078671	10/10/2002	PCT			yes-abstract
20.	WO03/024439	3/27/2003	PCT			
21.	WO03/057194	7/17/2003	PCT			
22.	WO03/091204	11/6/2003	PCT			
23.	WO03/072539	9/4/2003	PCT			
24.	WO03/088943	10/30/2003	PCT			
25.	WO03/088944	10/30/2003	PCT			
26.	WO04/022547	3/18/2004	PCT			
27.	WO04/037768	5/6/2004	PCT			
28.	WO04/037773	5/6/2004	PCT			
29.	WO04/016578	2/25/2004	PCT			
30.	WO04/037807	5/6/2004	PCT			
31.	WO04/039762	5/13/2004	PCT			
32.	WO04/039766	5/13/2004	PCT			
33.	WO05/004845	1/20/2005	PCT			
34.	WO05/004852	1/20/2005	PCT			

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

35.	WIRTH et al., Maillard Reaction of Lactose and Fluoxetine Hydrochloride, a Secondary Amine, J. of Pharm. Sciences 87(1):31-39 (1998).
36.	HAMMOUDA et al., Lactose-induced Discoloration of Amino Drugs in Solid Dosage Form, Kurze Originalmitteilungen 25:181 (1970).
37.	KUMAR et al., Maillard Reaction and Drug Stability, Royal Soc. of Chemistry 151:20-27 (1999).
38.	ZENG et al., The role of fine particle lactose on the dispersion and deaggregation of salbutamol sulphate in an air stream in vitro, Int'l J. of Pharmaceutics 176:99-110 (1998).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.